Thromb Haemost 1992; 68(03): 325-330
DOI: 10.1055/s-0038-1656374
Original Article
Schattauer GmbH Stuttgart

Fibrin Clot Lysis by Thrombolytic Agents Is Impaired in Newborns due to a Low Plasminogen Concentration

M Andrew
The Departments of Pediatrics and Medicine, McMaster University Health Sciences Centre, Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
,
L Brooker
The Departments of Pediatrics and Medicine, McMaster University Health Sciences Centre, Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
,
M Leaker
The Departments of Pediatrics and Medicine, McMaster University Health Sciences Centre, Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
,
B Paes
The Departments of Pediatrics and Medicine, McMaster University Health Sciences Centre, Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
,
J Weitz
The Departments of Pediatrics and Medicine, McMaster University Health Sciences Centre, Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 08 August 1991

Accepted after revision 09 April 1992

Publication Date:
04 July 2018 (online)

Summary

Although thrombolytic drugs have been extensively used in adults, there is sparse information on their effectiveness in newborns whose fibrinolytic system differs significantly from adults. The purpose of this study was to determine if low plasma levels of plasminogen in cord plasma limited the therapeutic effectiveness of thrombolytic agents. Urokinase (UK), streptokinase (SK) and tissue plasminogen activator (TPA) were compared for their ability to lyse washed 125I-labelled adult or cord fibrin clots suspended in cord or adult plasma. 125I-labelled fibrin clots were prepared by recalcifying cord or adult plasma spiked with labelled fibrinogen and then placed into cord or adult plasma which contained either saline or differing amounts of a specific thrombolytic agent. After a 60 min incubation, the remaining 125I-fibrin in clots released 125I-fibrin fragments, and concentrations of fibrinogen, α2-antiplasmin, and plasminogen in the bathing plasma were measured and compared to starting values. Cord fibrin clots were more resistant than adult fibrin clots to all thrombolytic drugs tested (p <0.001). On average, the cord system retained 27% more 125I-fibrin in clots, and released 32% less 125I-fibrin fragments into plasma. Fibrinogenolysis was also decreased in cord plasmas compared to adult plasmas. The degree of fibrinolysis and fibrinogenolysis in cord plasma increased to adult values when plasminogen concentrations were increased in the bathing plasma. Thus, cord fibrin clots have an impaired response to thrombolytic agents secondary to low levels of plasminogen. We speculate that the clinical response of newborns to thrombolytic agents is also impaired and will not be enhanced by increasing doses of thrombolytic agents but may be enhanced by increasing the concentration of plasminogen.

 
  • References

  • 1 Schmidt B, Zipursky A. Thrombotic disease in newborn infants. Clin Perinatol 1984; 11: 461-488
  • 2 Schmidt B, Andrew M. Neonatal thrombotic disease: Prevention, diagnosis and treatment. J Pediatr 1988; 113: 407-410
  • 3 Barnard DR, Hathaway WE. Neonatal thrombosis. Am J Pediatr Hematol/Oncol 1979; 1: 235-244
  • 4 O’Neill JA, Neblett WW III, Born ML. Management of major thromboembolic complications of umbilical artery catheters. J Pediatr Surg 1981; 16: 972-978
  • 5 Neal WA, Reynolds JW, Jarvis CW, Willians HJ. Umbilical artery catheterization: Demonstration of arterial thrombosis by aortography. Pediatrics 1972; 50: 06-13
  • 6 Goetzman BW, Stadalnik RC, Bogren HG, Blankenship WK, Ikeda RM, Thayer J. Thrombotic complications of umbilical artery catheters: A clinical and radiographic study. Pediatrics 1975; 56: 374-379
  • 7 Olinsky A, Aitken FG, Isdale JM. Thrombus formation after umbilical arterial catheterization: An angiographic study. S Afr Med J 1975; 49: 1467-1470
  • 8 Mokrohisky ST, Levine R, Blumhagen JD, Wesenberg RL, Simmons MA. Low positioning of umbilical artery catheters increases associated complications in newborn infants. N Engl J Med 1978; 299: 561-564
  • 9 Saia OS, Rubatelli FF, d’Elia RD, Marigo A, Perale R, Audino G, Lagarjolli G, Zanardo Y, Cantarutti F. Clinical and aortographic assessment of the complications of arterial catheterization. Eur J Pediatr 1978; 128: 169-179
  • 10 Wesstrom G, Finnstrom O, Stenport G. Umbilical artery catheterization in newborns. I. Thrombosis in relation to catheter type and position. Acta Paediatr Scand 1979; 68: 575-581
  • 11 Gilhooly JT, Lindenberg JA, Reynolds JW. Survey of umbilical catheter practices. Clin Res 1987; 34: 142A
  • 12 Verstraete M, Collen D. Thrombolytic therapy in the eighties. Blood 1986; 67: 1529-1541
  • 13 Marder VJ, Sherry S. Thrombolytic therapy: Current status (Part I). N Engl J Med 1988; 318: 1512-1520
  • 14 Marder VJ, Sherry S. Thrombolytic therapy: Current status (Part II). N Engl J Med 1988; 318: 1585-1593
  • 15 Corrigan JJ, Allen HD, Jeter M, Malone JM. Aortic thrombosis in a neonate: Failure of urokinase thrombolytic therapy. Am J Pediatr Hematol/Oncol 1982; 4: 243-247
  • 16 Delaplane D, Scott JP, Riggs TW, Silverman BL, Hung CE. Urokinase therapy for a catheter related right atrial thrombus. J Pediatr 1982; 100: 149-152
  • 17 Vailas GN, Brouillette RT, Scott JP, Shkolnik A, Conway J, Wiringa K. Neonatal aortic thrombosis: Recent experience. J Pediatr 1986; 109: 101-108
  • 18 Wessel DL, Keane JF, Fellows KE, Robichaud H, Lock JE. Fibrinolytic therapy for femoral arterial thrombosis after cardiac catheterization in infants and children. Am J Cardiol 1986; 58: 347-351
  • 19 Pangiglione G, Marasini M, Ribaldone D, Silvestri G, Tuo P, Garello-Canton L. Right atrial thrombosis in two premature infants: Successful treatment with urokinase and heparin. Eur Heart J 1986; 7: 1086-1089
  • 20 Emani A, Saldanha R, Knupp C, Kodroff M. Failure of systemic thrombolytic and heparin therapy in the treatment of neonatal aortic thrombosis. Pediatrics 1987; 79: 773-777
  • 21 Sadiq HF, Devaskar S, Keenan WJ, Weber TR. Broviac catheterization in low weight infants: Incidence and treatment of associated complications. Crit Care Med 1987; 15: 47-50
  • 22 Griffin MP, Casta A. Successful urokinase therapy for superior vena cava syndrome in premature infant. Am J Dis Child 1988; 142: 1267-1268
  • 23 Strife JL, Ball Jr WS, Towbin R, Keller MS, Dillon T. Arterial occlusion in neonates: use of fibrinolytic therapy. Radiology 1988; 166: 395-400
  • 24 Kennedy LA, Drummond WH, Knight ME, Williams JL, Millsaps MM. Successful thrombolysis by tissue plasminogen activator in neonatal aortic thrombosis. Pediatr Res 1989; 15: A391
  • 25 Andrew M, Paes B, Milner R, Johnston M, Powers P, Tollefsen DM. The development of the human coagulation system in the fullterm infant. Blood 1987; 70: 165-172
  • 26 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P. Development of the coagulation system in the healthy premature infant. Blood 1988; 72: 1651-1657
  • 27 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol/Oncol 1990; 12: 095-104
  • 28 Ambrus CM, Ambrus JL, Choi TS, Jung O, Mirand EA, Bartfay-Szabo A. The fibrinolysin system and its relationship to disease in the newborn. Am J Pediatr Hematol/Oncol 1979; 1: 251-260
  • 29 Corrigan JJ. Neonatal thrombosis and the thrombolytic system: Pathophysiology and therapy. Am J Pediatr Hematol/Oncol 1988; 10: 83-91
  • 30 Corrigan JJ, Sleeth JJ, Jeter M, Lox CD. Newborn’s fibrinolytic mechanism: Components and plasmin generation. Am J Hematol 1989; 32: 273-278
  • 31 Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants, age-related differences and therapeutic implication. Clin Pharm 1980; 5: 485-527
  • 32 Straughn W, III Wagner RH. A simple method for preparing fibrinogen. Thromb Diath Haemorrh 1966; 6: 198-206
  • 33 Ikeno LC, Bowen BM, Der M. Commercial production of 125I-fibrinogen for injection. J Radioanal Chem 1981; 65: 179-188
  • 34 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
  • 35 Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
  • 36 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
  • 37 Weitz JI, Berry L, Ginsberg J. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis. J Clin Invest 1991; 87: 1080-1092
  • 38 Sabovic M, Lijnen HR, Keber D, Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemostas 1990; 64: 450-454
  • 39 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of hyman clots with fibrin specific and non-fibrin specific plasminogen activities. Thromb Haemostas 1989; 62: 1083-1087
  • 40 Suarez CR, Menendez CE, Walenga JM, Fareed J. Neonatal and maternal hemostasis: Value of molecular markers in the assessment of hemostatic status. Semin Thromb Haemostas 1984; 10 (4) 280-284
  • 41 Andrew M, O’Brodovich H, Mitchell L. Fetal lam coagulation during normal birth. Am J Hematol 1988; 28: 116-118
  • 42 Reverdiau-Moalic P, Gruel Y, Delahausse B, Rupin A, Huart MC, Body G, Leroy J. Comparative study of the fibrinolytic system in human fetuses and in pregnant women. Thromb Res 1991; 61: 489-499
  • 43 Estelles A, Aznar J, Gilabert J, Parrilla JJ. Dysfunctional plasminogen in fullterm newborns. Pediatr Res 1980; 14: 1180-1185
  • 44 Al Hilali MM, Gilliver BE. Physiological activation of plasminogen in full term newborn infants. J Clin Pathol 1984; 37: 1264-1267
  • 45 Benavent A, Estelles A, Aznar J, Martinez-Sales V, Gilabert J, Fornas E. Dysfunctional plasminogen in full term newborn – study active site plasmin. Thromb Haemostas 1984; 51: 67-70
  • 46 Edelberg JM, Enghild JJ, Pizzo SV, Gonzales-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990; 86: 106-112
  • 47 Galanakis DK, Mossesson MW. Evaluation of the role of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen. Blood 1976; 48: 109-118
  • 48 Gralnick HR, Gilveber H, Abrams E. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Engl J Med 1978; 299: 221-226